04/06/2024  10:28:31 Var. +0.028 Volume Denaro10:28:31 Lettera10:28:31 Capitalizzazione di mercato Dividend Y. Rapporto P/E
2.698EUR +1.05% -
Fatturato: -
2.698Quantità in denaro: - 2.730Quantità in lettera: - -EUR - -

Descrizione business

Idorsia Ltd is an independent biopharmaceutical company specialized in the discovery and development of small molecule therapeutics to meet significant unmet medical needs. Idorsia has a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. Idorsia directly benefits from Actelion’s 19-year history and experience, inheriting Actelion’s established and validated drug discovery engine and a strong cross-section of its development organization. Idorsia’s pipeline will be developed by its own development organization. Headquartered in Allschwil, Switzerland, Idorsia was incorporated on 2 March 2017 and was launched on 16 June 2017.
 

Consiglio di amministrazione & Consiglio di sorveglianza

CEO
Jean-Paul Clozel
Consiglio di amministrazione
André C. Muller, Martine Clozel, Guy Braunstein, Alberto Gimona
Consiglio di sorveglianza
Mathieu Simon, Joern Aldag, Jean-Paul Clozel, Felix R. Ehrat, Srishti Gupta, Peter Kellogg, Sophie Kornowski, Sandy Mahatme
 

Dati aziendali

Name: Idorsia Ltd
Indirizzo: Hegenheimermattweg 91,CH-4123 Allschwil
Telefono: +41-58-8440000
Fax: -
E-mail: info@idorsia.com
Internet: https://www.idorsia.com
Industria: Healthcare
Settore: Pharmaceutical Industry
Sub settore: Pharmaceuticals
Fine dell'anno finanziario: 31/12
Flottante libero: -
Data dell'IPO: 16/06/2017

Rapporti con gli investitori

Name: Andrew C. Weiss
IR telefono: +41-58-8441010
IR Fax: -
IR e-mail: investor.relations@idorsia.com

Company calendar

CW 24 | 13/06/2024 General Shareholder Meeting
CW 30 | 25/07/2024 Interim Report 2nd Quarter/6 Months
 

Principali azionisti

Altri
 
56.00%
Jean-Paul & Martine Clozel
 
25.88%
Idorsia (treasury shares)
 
5.14%
Cilag Holding AG
 
5.10%
Rudolf Maag
 
4.81%
The Capital Group Companies, Inc.
 
3.07%